AKRO Akero Therapeutics Inc

Price (delayed)

$17.66

Market cap

$983.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.28

Enterprise value

$740.02M

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, ...

Highlights
Akero Therapeutics's EPS has increased by 32% YoY and by 8% QoQ
AKRO's equity has surged by 70% year-on-year but it is down by 5% since the previous quarter
Akero Therapeutics's quick ratio has decreased by 34% QoQ but it has increased by 32% YoY
AKRO's debt has surged by 143% year-on-year
AKRO's net income is down by 3.6% QoQ

Key stats

What are the main financial stats of AKRO
Market
Shares outstanding
55.71M
Market cap
$983.83M
Enterprise value
$740.02M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.68
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$117.07M
EBITDA
-$116.8M
Free cash flow
-$122.25M
Per share
EPS
-$2.28
Free cash flow per share
-$2.2
Book value per share
$10.49
Revenue per share
$0
TBVPS
$11.42
Balance sheet
Total assets
$635.33M
Total liabilities
$52.2M
Debt
$25.73M
Equity
$583.14M
Working capital
$547.53M
Liquidity
Debt to equity
0.04
Current ratio
20.25
Quick ratio
19.5
Net debt/EBITDA
2.09
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-23.9%
Return on equity
-26.1%
Return on invested capital
-59.7%
Return on capital employed
-19.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKRO stock price

How has the Akero Therapeutics stock price performed over time
Intraday
5.5%
1 week
8.08%
1 month
33.69%
1 year
-61.35%
YTD
-67.77%
QTD
-65.09%

Financial performance

How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$136.42M
Net income
-$119.63M
Gross margin
N/A
Net margin
N/A
Akero Therapeutics's operating income has decreased by 12% YoY and by 8% from the previous quarter
AKRO's net income is down by 3.6% QoQ

Growth

What is Akero Therapeutics's growth rate over time

Valuation

What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
1.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has increased by 32% YoY and by 8% QoQ
The stock's P/B is 70% below its last 4 quarters average of 5.6 and 62% below its 5-year quarterly average of 4.4
AKRO's equity has surged by 70% year-on-year but it is down by 5% since the previous quarter

Efficiency

How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on invested capital has surged by 100% YoY and by 46% QoQ
Akero Therapeutics's return on equity has surged by 57% YoY and by 10% QoQ
The ROA has soared by 54% YoY and by 9% from the previous quarter

Dividends

What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKRO.

Financial health

How did Akero Therapeutics financials performed over time
The company's total assets has surged by 67% YoY but it fell by 4.3% QoQ
The total liabilities is up by 45% year-on-year and by 10% since the previous quarter
AKRO's debt is 96% smaller than its equity
AKRO's debt has surged by 143% year-on-year
AKRO's equity has surged by 70% year-on-year but it is down by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.